Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

Fig. 1

ROC curve analysis of the association between TMB and DCB in young and elderly patients in NSCLC. ROC curves of (a) Rizvi cohort, (b) Hellmann cohort. ROC: receiver operator characteristic; TMB: tumor mutation burden; DCB: durable clinical benefit; NSCLC: non-small cell lung cancer; AUC: area under curve; CI: confidence interval

Back to article page